BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 5.5% Following Earnings Beat

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shot up 5.5% on Tuesday following a better than expected earnings announcement. The company traded as high as $5.70 and last traded at $5.56. 774,886 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 3,331,300 shares. The stock had previously closed at $5.27.

The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. The company’s revenue was up 34.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.28) earnings per share.

Analyst Upgrades and Downgrades

BCRX has been the topic of several research analyst reports. JMP Securities lifted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Institutional Trading of BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of BCRX. Fifth Third Bancorp grew its position in BioCryst Pharmaceuticals by 17,500.0% in the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,500 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in BioCryst Pharmaceuticals by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 2,388 shares in the last quarter. Quarry LP purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at approximately $54,000. Tower Research Capital LLC TRC boosted its holdings in BioCryst Pharmaceuticals by 131.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 5,912 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. acquired a new position in BioCryst Pharmaceuticals during the 4th quarter worth approximately $64,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 0.2 %

The business has a 50 day moving average price of $4.90 and a 200-day moving average price of $5.45. The firm has a market capitalization of $1.09 billion, a PE ratio of -4.46 and a beta of 1.96.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.